Skip to main content

Rock Springs Capital Management LP's Form 4 filing

Xilio Therapeutics, Inc. (XLO) · filed Oct 26, 2021

Accession no.
0001104659-21-130031
Filed
Oct 26, 2021, 5:04 PM ET
Trade date
Oct 26, 2021
Filing delay
Same day
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 3 non-derivative transactions and 2 derivative transactions. Open-market purchases total $8.00M. It was filed on the trade date.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Rock Springs Capital Management LPCIK 000159572510% Owner
Rock Springs Capital Master Fund LPCIK 000173539310% Owner
Rock Springs Capital LLCCIK 000173539710% Owner
Four Pines Master Fund LPCIK 000188868510% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Oct 26, 2021Common StockCConversionAcquired+756,472–F1–756,472Indirect
Oct 26, 2021Common StockCConversionAcquired+151,294–F1–151,294Indirect
Oct 26, 2021Common StockPPurchaseAcquired+500,000$16.00+$8,000,0001,256,472Indirect

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Oct 26, 2021Common StockCConversionDisposed−756,472–F1–0Indirect
Oct 26, 2021Common StockCConversionDisposed−151,294–F1–0Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

The Series C Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on a 9.5:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series C Preferred Stock had no expiration date.

Referenced by the price of 2 transactions in Table I and 2 transactions in Table II.

Read the full filing on SEC EDGAR (opens in a new tab)